Key Points
-
Reduced immune regulation seems to be a feature of a subgroup of individuals with type 1 diabetes mellitus (T1DM)
-
Several genetic risk factors for T1DM are associated with differential functionality of immune modulation
-
Most immune intervention strategies that have been assessed for their efficacy in intervening in the immunopathogenesis of T1DM suppress, rather than modulate, the autoimmune response against pancreatic islets
-
The newly appreciated heterogeneity in T1DM implies that a personalized approach could be used to treat this disease; treatments that modify the immune system might be ideally suited to this purpose
Abstract
Type 1 diabetes mellitus (T1DM) is the result of autoimmune destruction of pancreatic β cells in genetically predisposed individuals with impaired immune regulation. The insufficiency in the modulation of immune attacks on the β cells might be partly due to genetic causes; indeed, several of the genetic variants that predispose individuals to T1DM have functional features of impaired immune regulation. Whilst defects in immune regulation in patients with T1DM have been identified, many patients seem to have immune regulatory capacities that are indistinguishable from those of healthy individuals. Insight into the regulation of islet autoimmunity might enable us to restore immune imbalances with therapeutic interventions. In this Review, we discuss the current knowledge on immune regulation and dysfunction in humans that is the basis of tissue-specific immune regulation as an alternative to generalized immune suppression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gepts, W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14, 619–663 (1965).
Itoh, N. et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92, 2313–2322 (1993).
Sibley, R., Sutherland, D. E. R., Goetz, F. & Michael, A. F. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab. Invest. 53, 132–144 (1985).
Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209, 51–60 (2012).
Keenan, H. A. et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59, 2846–2853 (2010).
Roep, B. O. & Peakman, M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat. Rev. Immunol. 10, 145–152 (2010).
Peterson, L. D., van der Keur, M., de Vries, R. R. & Roep, B. O. Autoreactive and immunoregulatory T-cell subsets in insulin-dependent diabetes mellitus. Diabetologia 42, 443–449 (1999).
Roep, B. O. et al. Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J. Autoimmun. 13, 267–282 (1999).
Arif, S. et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113, 451–463 (2004).
Tree, T. I., Duinkerken, G., Willemen, S., de Vries, R. R. & Roep, B. O. HLA-DQ-regulated T-cell responses to islet cell autoantigens insulin and GAD65. Diabetes 53, 1692–1699 (2004).
Durinovic-Bello, I. et al. Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun. 11, 188–193 (2010).
Bach, J. M. et al. High affinity presentation of an autoantigenic peptide in Type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J. Autoimmun. 10, 375–386 (1997).
Danke, N. A., Yang, J., Greenbaum, C. & Kwok, W. W. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J. Autoimmun. 25, 303–311 (2005).
Viglietta, V., Kent, S. C., Orban, T. & Hafler, D. A. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J. Clin. Invest. 109, 895–903 (2002).
Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490–500 (2010).
Miyara, M. & Sakaguchi, S. Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns. Immunol. Cell Biol. 89, 346–351 (2011).
Bach, J. F. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3, 189–198 (2003).
Roncarolo, M. G. & Levings, M. K. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr. Opin. Immunol. 12, 676–683 (2000).
Buckner, J. H. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10, 849–859 (2010).
Abbas, A. K. et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat. Immunol. 14, 307–308 (2013).
Wildin, R. S. et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18–20 (2001).
Tritt, M., Sgouroudis, E., d'Hennezel, E., Albanese, A. & Piccirillo, C. A. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 57, 113–123 (2008).
Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).
Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007 (2009).
D'Alise, A. M. et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl Acad. Sci. USA 105, 19857–19862 (2008).
Sgouroudis, E., Albanese, A. & Piccirillo, C. A. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J. Immunol. 181, 6283–6292 (2008).
Goudy, K. S. et al. Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J. Immunol. 186, 3779–3786 (2011).
Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871–1878 (2010).
Masteller, E. L. et al. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol. 175, 3053–3059 (2005).
Tarbell, K. V., Yamazaki, S., Olson, K., Toy, P. & Steinman, R. M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199, 1467–1477 (2004).
Lindley, S. et al. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 54, 92–99 (2005).
Brusko, T. M., Wasserfall, C. H., Clare-Salzler, M. J., Schatz, D. A. & Atkinson, M. A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54, 1407–1414 (2005).
Glisic, S. & Jailwala, P. Interaction between Treg apoptosis pathways, Treg function and HLA risk evolves during type 1 diabetes pathogenesis. PLoS ONE 7, e36040 (2012).
Glisic-Milosavljevic, S. et al. Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin. Exp. Immunol. 150, 75–82 (2007).
Glisic-Milosavljevic, S. et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS ONE 2, e146 (2007).
Haseda, F., Imagawa, A., Murase-Mishiba, Y., Terasaki, J. & Hanafusa, T. CD4+ CD45RA− FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin. Exp. Immunol. 173, 207–216 (2013).
Lawson, J. M. et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353–359 (2008).
Schneider, A. et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181, 7350–7355 (2008).
Tree, T. I., Roep, B. O. & Peakman, M. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann. NY Acad. Sci. 1079, 9–18 (2006).
Garg, G. et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J. Immunol. 188, 4644–4653 (2012).
Long, S. A. et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes 59, 407–415 (2010).
Long, S. A. et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4+ T cells. Genes Immun. 12, 116–125 (2010).
Marwaha, A. K. et al. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 185, 3814–3818 (2010).
McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918–3926 (2011).
Hulme, M. A., Wasserfall, C. H., Atkinson, M. A. & Brusko, T. M. Central role for interleukin-2 in type 1 diabetes. Diabetes 61, 14–22 (2012).
Putnam, A. L. et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58, 652–662 (2009).
Ferraro, A. et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60, 2903–2913 (2011).
Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K. & Morgan, N. G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155, 173–181 (2009).
Gregori, S., Goudy, K. S. & Roncarolo, M. G. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front. Immunol. 3, 30 (2012).
Bacchetta, R. et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J. Exp. Med. 179, 493–502 (1994).
Roncarolo, M. G. et al. Autoreactive T cell clones specific for class I and class II HLA antigens isolated from a human chimera. J. Exp. Med. 167, 1523–1534 (1988).
Serafini, G. et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica 94, 1415–1426 (2009).
Petrich de Marquesini, L. G. et al. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 53, 1451–1460 (2010).
Sanda, S., Roep, B. O. & von Herrath, M. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin. Immunol. 127, 138–143 (2008).
Tree, T. I. et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59, 1451–1460 (2010).
Magnani, C. F. et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur. J. Immunol. 41, 1652–1662 (2011).
Veldman, C., Hohne, A., Dieckmann, D., Schuler, G. & Hertl, M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol. 172, 6468–6475 (2004).
Ward, F. J. et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood 111, 680–687 (2008).
Gianfrani, C. et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J. Immunol. 177, 4178–4186 (2006).
Meiler, F. et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205, 2887–2898 (2008).
Maizels, R. M. & Smith, K. A. Regulatory T cells in infection. Adv. Immunol. 112, 73–136 (2011).
McSorley, H. J. & Maizels, R. M. Helminth infections and host immune regulation. Clin. Microbiol. Rev. 25, 585–608 (2012).
Tian, J. et al. Modulating autoimmune response to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat. Med. 12, 1348–1353 (1996).
Tisch, R., Liblau, R. S., Yang, X. D., Liblau, P. & McDevitt, H. O. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 47, 894–899 (1998).
Tisch, R. et al. Antigen-specific mediated suppression of β cell autoimmunity by plasmid DNA vaccination. J. Immunol. 166, 2122–2132 (2001).
Thrower, S. L. et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin. Exp. Immunol. 155, 156–165 (2009).
Campbell, J. D. et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J. Exp. Med. 206, 1535–1547 (2009).
Patel, D. et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J. Allergy Clin. Immunol. 131, 103–109 (2013).
Tsai, S. et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32, 568–580 (2010).
Kalampokis, I., Yoshizaki, A. & Tedder, T. F. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 15 (Suppl. 1), S1 (2013).
Hussain, S. & Delovitch, T. L. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J. Immunol. 179, 7225–7232 (2007).
Hu, C. Y. et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857–3867 (2007).
Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143–2152 (2009).
Nikolic, T. & Roep, B. O. Regulatory multitasking of tolerogenic dendritic cells—lessons taken from vitamin d3-treated tolerogenic dendritic cells. Front. Immunol. 4, 113 (2013).
Kleijwegt, F. S. & Roep, B. O. Infectious tolerance as candidate therapy for type 1 diabetes: transfer of immunoregulatory properties from human regulatory T cells to other T cells and proinflammatory dendritic cells. Crit. Rev. Immunol. 33, 415–434 (2013).
Kleijwegt, F. S. et al. Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J. Immunol. 187, 6357–6364 (2011).
Peterson, L. D., van der Keur, M., de Vries, R. R. & Roep, B. O. Autoreactive and immunoregulatory T-cell subsets in insulin-dependent diabetes mellitus. Diabetologia 42, 443–449 (1999).
Naik, R. G. et al. Precursor frequencies of T-cells reactive to insulin in recent onset type 1 diabetes mellitus. J. Autoimmun. 23, 55–61 (2004).
Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337–338 (2004).
Geiler, J., Buch, M. & McDermott, M. F. Anti-TNF treatment in rheumatoid arthritis. Curr. Pharm. Des. 17, 3141–3154 (2011).
Skyler, J. S. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial–Type 1. Diabetes Care 28, 1068–1076 (2005).
Bougneres, P. F. et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N. Engl. J. Med. 318, 663–670 (1988).
Silverstein, J. et al. Immunosuppression with azathioprine and prednisone in recent onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319, 599–604 (1988).
Feutren, G. & Mihatsch, M. J. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N. Engl. J. Med. 326, 1654–1660 (1992).
Couri, C. E. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301, 1573–1579 (2009).
Voltarelli, J. C. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297, 1568–1576 (2007).
Gale, E. A. M. Can. we change the course of β-cell destruction in type 1 diabetes? N. Engl. J. Med. 346, 1740–1742 (2002).
Noon, L. Prophylactic inoculation against hay fever. Lancet 177, 1572–1573 (1911).
Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61, 2066–2073 (2012).
Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412–419 (2011).
Roep, B. O. New hope for immune intervention therapy in type 1 diabetes. Lancet 378, 376–378 (2011).
Buzzetti, R. et al. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 60, 3067–3072 (2011).
Qu, H. Q. & Polychronakos, C. The effect of the MHC locus on autoantibodies in type 1 diabetes. J. Med. Genet. 46, 469–471 (2009).
Kobayashi, T. et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16, 780–788 (1993).
Barker, J. M. et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J. Clin. Endocrinol. Metab. 89, 3896–3902 (2004).
Howson, J. M. et al. Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. Diabetes 60, 2635–2644 (2011).
Ludvigsson, J. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366, 433–442 (2012).
Raz, I. et al. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358, 1749–1753 (2001).
Bonifacio, E., Ziegler, A., Achenbach, P., Barker, J. & Eisenbarth, G. Translating mucosal antigen based prevention of autoimmune diabetes to human. Novartis Found. Symp. 292, 187–199 (2008).
Fourlanos, S. et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60, 1237–1245 (2011).
Nanto-Salonen, K. et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372, 1746–1755 (2008).
Lesterhuis, W. J. et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 17, 5725–5735 (2011).
Roep, B. O., Atkinson, M. & von Herrath, M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat. Rev. Immunol. 4, 989–997 (2004).
Huurman, V. A., Decochez, K., Mathieu, C., Cohen, I. R. & Roep, B. O. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab. Res. Rev. 23, 269–275 (2007).
Ludvigsson, J. et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909–1920 (2008).
Roep, B. O. et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci. Transl. Med. 5, 191ra82 (2013).
Huurman, V. A. et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin. Exp. Immunol. 152, 488–497 (2008).
Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).
Oresic, M. et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J. Exp. Med. 205, 2975–2984 (2008).
Diabetes Prevention Trial–Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685–1691 (2002).
Long, S. A. et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61, 2340–2348 (2012).
Roep, B. O. Immune intervention therapy in type 1 diabetes: safety first. Lancet Diabetes Endocrinol. 1, 263–265 (2013).
Harlan, D. M., Kenyon, N. S., Korsgren, O. & Roep, B. O. Current advances and travails in islet transplantation. Diabetes 58, 2175–2184 (2009).
Hilbrands, R. et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 58, 2267–2276 (2009).
Huurman, V. A. et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3, e2435 (2008).
Velthuis, J. H. et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59, 1721–1730 (2010).
Gitelman, S. E. et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 1, 306–316 (2013).
Rigby, M. R. et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 1, 284–294 (2013).
Roncarolo, M. G. & Battaglia, M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7, 585–598 (2007).
Brusko, T. & Bluestone, J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur. J. Immunol. 38, 931–934 (2008).
Marek-Trzonkowska, N. et al. Administration of CD4+CD25highCD127− regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 35, 1817–1820 (2012).
Welters, M. J. et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl Acad. Sci. USA 107, 11895–11899 (2010).
Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823–832 (2001).
Brusko, T. M. et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS ONE 5, e11726 (2010).
Kleijwegt, F. S. et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J. Immunol. 185, 1412–1418 (2010).
Roep, B. O. et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin. Exp. Immunol. 159, 338–343 (2010).
van Halteren, A. G., Kardol, M. J., Mulder, A. & Roep, B. O. Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. Diabetologia 48, 75–82 (2005).
van Halteren, A. G., Tysma, O. M., van Etten, E., Mathieu, C. & Roep, B. O. 1α,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J. Autoimmun. 23, 233–239 (2004).
Unger, W. W., Laban, S., Kleijwegt, F. S., van der Slik, A. R. & Roep, B. O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 39, 3147–3159 (2009).
Cobbold, S. P. et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106, 12055–12060 (2009).
Qin, S. et al. “Infectious” transplantation tolerance. Science 259, 974–977 (1993).
Sanchez-Fueyo, A. et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4, 1093–1101 (2003).
Sumitomo, S. et al. Transcription factor early growth response 3 is associated with the TGF-β1 expression and the regulatory activity of CD4-positive T cells in vivo. J. Immunol. 191, 2351–2359 (2013).
Matthews, J. B. et al. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin. Exp. Immunol. 160, 176–184 (2010).
Huurman, V. A. et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am. J. Transplant. 9, 382–388 (2009).
Benoist, C. & Mathis, D. Treg cells, life history, and diversity. Cold Spring Harb. Perspect. Biol. 4, a007021 (2012).
Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911 (2009).
Vignali, D. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol. 8, 523–532 (2008).
Gagliani, N. et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 19, 739–746 (2013).
Gregori, S. et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116, 935–944 (2010).
Barchet, W. et al. Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood 107, 1497–1504 (2006).
Battaglia, M. & Roncarolo, M. G. The role of cytokines (and not only) in inducing and expanding T regulatory type 1 cells. Transplantation 77 (1 Suppl.), S16–S18 (2004).
Gandhi, R. et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells. Nat. Immunol. 11, 846–853 (2010).
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. & Enk, A. H. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213–1222 (2000).
Kemper, C. et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421, 388–392 (2003).
Levings, M. K. et al. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166, 5530–5539 (2001).
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002).
Moran, A. et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381, 1905–1915 (2013).
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to all aspects of the manuscript.
Corresponding author
Ethics declarations
Competing interests
B. O. Roep has consulted for Andromeda Biotech, Diamyd Medical, GlaxoSmithKline and Lilly. B. O. Roep has performed contract research for Andromeda Biotech and Bayhill Therapeutics. T. I. M. Tree declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Roep, B., Tree, T. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol 10, 229–242 (2014). https://doi.org/10.1038/nrendo.2014.2
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2014.2
This article is cited by
-
Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot
Reviews in Endocrine and Metabolic Disorders (2022)
-
Japanese Type 1 Diabetes Database Study (TIDE-J): rationale and study design
Diabetology International (2022)
-
The all-cause mortality and risk factors for mortality within five years among prevalent Type 1 Diabetes Mellitus Patients
International Journal of Diabetes in Developing Countries (2019)
-
Beta cells in type 1 diabetes: mass and function; sleeping or dead?
Diabetologia (2019)
-
Immunological biomarkers for the development and progression of type 1 diabetes
Diabetologia (2018)